These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10168356)

  • 1. The role of alpha-agonists in glaucoma therapy.
    Robin AL
    Curr Opin Ophthalmol; 1997 Apr; 8(2):42-9. PubMed ID: 10168356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures.
    Chevrier RL; Assalian A; Duperré J; Lesk MR
    Ophthalmic Surg Lasers; 1999 Mar; 30(3):199-204. PubMed ID: 10100253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy.
    Shin DH; Glover BK; Cha SC; Kim YY; Kim C; Nguyen KD
    Am J Ophthalmol; 1999 May; 127(5):511-5. PubMed ID: 10334342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exposure to topical apraclonidine in children with glaucoma.
    Wright TM; Freedman SF
    J Glaucoma; 2009; 18(5):395-8. PubMed ID: 19525731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brimonidine 0.2% versus apraclonidine 0.5% for prevention of intraocular pressure elevations after anterior segment laser surgery.
    Chen TC; Ang RT; Grosskreutz CL; Pasquale LR; Fan JT
    Ophthalmology; 2001 Jun; 108(6):1033-8. PubMed ID: 11382625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocular perfusion pressure and visual field indice modifications induced by alpha-agonist compound (clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2%) topical administration. An acute study on primary open-angle glaucoma patients.
    Costagliola C; Parmeggiani F; Ciancaglini M; D'Oronzo E; Mastropasqua L; Sebastiani A
    Ophthalmologica; 2003; 217(1):39-44. PubMed ID: 12566871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selectivity of site of action and systemic effects of topical alpha agonists.
    Robin AL; Burnstein Y
    Curr Opin Ophthalmol; 1998 Apr; 9(2):30-3. PubMed ID: 10180510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brimonidine 0.15% versus apraclonidine 0.5% for prevention of intraocular pressure elevation after anterior segment laser surgery.
    Chen TC
    J Cataract Refract Surg; 2005 Sep; 31(9):1707-12. PubMed ID: 16246772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure.
    Yüksel N; Karabaş L; Altintaş O; Yildirim Y; Cağlar Y
    Ophthalmologica; 2002; 216(1):45-9. PubMed ID: 11901288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Apraclonidine Maximum-Tolerated Medical Therapy Study Group.
    Robin AL; Ritch R; Shin DH; Smythe B; Mundorf T; Lehmann RP
    Am J Ophthalmol; 1995 Oct; 120(4):423-32. PubMed ID: 7573299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical apraclonidine hydrochloride in eyes with poorly controlled glaucoma. The Apraclonidine Maximum Tolerated Medical Therapy Study Group.
    Robin AL; Ritch R; Shin D; Smythe B; Mundorf T; Lehmann RP
    Trans Am Ophthalmol Soc; 1995; 93():421-38; discussion 439-41. PubMed ID: 8719690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High incidence of topical allergic reactions to 1% apraclonidine.
    Feibel RM
    Arch Ophthalmol; 1995 Dec; 113(12):1579-80. PubMed ID: 7487638
    [No Abstract]   [Full Text] [Related]  

  • 13. Is brimonidine ophthalmic a safe therapy for infants?
    Daubert GP
    J Clin Pharm Ther; 2006 Jun; 31(3):289-92. PubMed ID: 16789995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect and side effects of apraclonidine].
    Stewart WC
    Klin Monbl Augenheilkd; 1996 Jul; 209(1):A7-13. PubMed ID: 8965469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of apraclonidine on short-term outcome of glaucoma surgery.
    Azuara-Blanco A; Araujo SV; Lu DW; Lesk MR; Katz LJ; Spaeth GL
    J Glaucoma; 1996 Apr; 5(2):117-9. PubMed ID: 8795743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apraclonidine and anterior segment laser surgery. Comparison of 0.5% versus 1.0% apraclonidine for prevention of postoperative intraocular pressure rise.
    Rosenberg LF; Krupin T; Ruderman J; McDaniel DL; Siegfried C; Karalekas DP; Grewal RK; Gieser DK; Williams R
    Ophthalmology; 1995 Sep; 102(9):1312-8. PubMed ID: 9097768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of topical apraclonidine on the frequency of intraocular pressure elevations after combined extracapsular cataract extraction and trabeculectomy.
    Robin AL
    Ophthalmology; 1993 May; 100(5):628-33. PubMed ID: 8098520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of intraocular pressure increases with 0.5% apraclonidine after dilated fundus examination in patients with chronic open-angle glaucoma.
    Nishimoto JH; Chang FW; Tang IH; Kolin T
    J Am Optom Assoc; 1999 Apr; 70(4):233-9. PubMed ID: 10457699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Alpha-2 adrenergic agonists in the treatment of glaucoma].
    Apătăchioae I; Chiseliţă D
    Oftalmologia; 1999; 47(2):35-40. PubMed ID: 10641099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of apraclonidine ophthalmic solution (Iopidine) in presumed silicon oil-induced glaucoma and primary open-angle glaucoma.
    Gramer E; Busche S; Kampik A; Parsons D
    Graefes Arch Clin Exp Ophthalmol; 1995 Jan; 233(1):13-20. PubMed ID: 7721118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.